Enanta Pharmaceuticals Inc
ENTA
Get informed when a big investor buys or sells
+ FollowMarket Cap$400.41M
Close$
$-7.91
158.8% downside
Current Fair Value
158.8% downsideOvervalued by 158.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $400.41 Million |
|---|---|
| Enterprise Value | $422.65 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.84 |
| Beta | 0.97 |
| Outstanding Shares | 21,380,000 |
Return
| Return on Equity | -62.56% |
|---|---|
| Return on Assets | -21.30% |
| Return on Invested Capital | -22.04% |
Valuation & Multiples
| P/E Ratio | -5.03 |
|---|---|
| PEG | -73.63 |
| Price to Sales | 4.48 |
| Price to Book Ratio | 3.36 |
| Enterprise Value to Revenue | 6.48 |
| Enterprise Value to EBIT | -7.9 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.55 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
$16.76 M
Average shareholder expectationNext Earnings Call
Expected Date
November 16, 2026
EPS Estimate
$-0.64
Average shareholder expectationRevenue Estimate
$16.18 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 38.12% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 19.86%▼ 105.37% |
|---|---|
| Total Invested | $61.88M▼ 81.70% |
| Investors Holding | 39▼ 96.00% |
ESG Score
No data
About Enanta Pharmaceuticals Inc
CEO: Jay Luly